| Name | Wnt-C59 |
| Description | Wnt-C59 (C59) is a highly effective and specific Wnt signaling antagonis with PORCN enzymatic activity. |
| Cell Research | Wnt-C59 (C59) is dissolved in DMSO (10 mM) and stored, and then diluted with appropriate medium before use[1]. Approximately, 1×104 cells are seeded in 24-well plates, and Wnt-C59 (5 μM, 10 μM, and 20 μM) is added the next day. Each group is tested in triplicate and control groups with addition of DMSO are also established. Cell confluence is determined by microscopy at 24, 48, 72, and 96 hours after seeding of cells. The IC50 of Wnt-C59 is determined by MTT assay, using 96-well dishes. Next day, various concentrations of Wnt-C59 are added, and cellular viabilities are measured by a spectrophotometer at both 24 and 48 hours. For sphere formation, approximately one hundred cells are seeded onto the Low Cell Bind Surface 24-well Nunc dish. Each group is done in triplicate and each well had 2 mL medium. Media are changed twice a week, and only half of the media is changed each time. Approximately, 1×103 cells are seeded for each well in the sphere inhibition assay. At 1 to 5 days after plating, all tested cells formed small spheres. Five days later, Wnt-C59 (1 μM, 5 μM, and 20 μM) is added into experimental groups. Abilities for cell growth and sphere images are compared and recorded at the end of the first, second, and third weeks after addition of Wnt-C59, or DMSO in control groups. The sphere growths are observed and recorded daily under microscopy, and the area of spheres is analyzed using Metamorph and recorded as average area (μm2)[1]. |
| Kinase Assay | Aurora A radioactive Flashplate enzyme assay: Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates. |
| In vitro | In female nude mice with independently transplanted in-situ MMTV-WNT1 tumors, Wnt-C59 (10 mg/kg) effectively reduces the expression of β-catenin-targeted genes and decreases Wnt pathway activity, suppressing tumor cell growth. Additionally, in 14CREER/Rosa-SmoM2 mice, topical administration of Wnt-C59 (5 mg/kg) inhibits cell proliferation. |
| In vivo | In PORCN-deficient HT1080 cells transfected with PORCN, Wnt-C59 (100 nM) inhibits PORCN activity. Similarly, in HeLa cells transfected with WNT3A-V5, Wnt-C59 (10 -100 nM) suppresses the activity of the PORCN acyltransferase. |
| Storage | store at low temperature,keep away from direct sunlight | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.27 mM), Sonication is recommended.
Ethanol : 7.6 mg/mL (20.03 mM), Sonication is recommended.
DMSO : 38.32 mg/mL (100.99 mM), Sonication is recommended.
|
| Keywords | βcatenin | Wnt-C-59 | Wnt-C59 | WntC59 | Wnt/β-catenin | Wnt/betacatenin | Wnt/b-catenin | Wnt C59 | Wnt | Porcn | C-59 | C 59 | beta-catenin | betacatenin | bcatenin |
| Inhibitors Related | Chlorquinaldol | Urea | Wnt pathway activator 1 | Neohesperidin | XAV-939 | Ethyl linoleate | Monensin sodium salt | Nimbolide | Isoquercetin | (±)-Nornicotine | Methyl Vanillate | Bisdemethoxycurcumin |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Neural Regeneration Compound Library | Bioactive Compound Library | Cancer Cell Differentiation Compound Library | Hematonosis Compound Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Neuroprotective Compound Library | Anti-Fibrosis Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library |
United States
